Developer of bio-pharmaceutical medicines created to offer new pathways that treat serious and widespread unmet medical needs. The company's bio-pharmaceutical products include investigational drugs which are used for the treatment of cancer, auto-immune disease and chronic pain, enabling patients to recover from chronic illness.
Year Founded
1990
Employees
509
RevenueTTM 3Q2018
$1.2 B
Net IncomeTTM 3Q2018
$745.7 M
General Information
-
Website
-
Business Status
Profitable
-
Ownership Status
Publicly Held
-
Financing Status
Corporate Backed or Acquired
Nektar Therapeutics News and Updates
Sjogren's Syndrome Market Size Increase with Significant CAGR by ...
GlobeNewswire | September 21, 2023
Prominent Board Member Makes Notable Stock Acquisition at ...
Best Stocks | September 21, 2023
Director at Nektar Therapeutics Receives Valuable Stock Options A ...
Best Stocks | September 21, 2023
Nektar Therapeutics Board Member Awarded $59K Worth of Stock Options - Nektar Therapeutics (NASDAQ:NKTR)
Benzinga | September 21, 2023
Oral Insulin Market is Thriving Worldwide with a CAGR of 34.6%
openPR | September 21, 2023
NK Cell Therapy Clinical Trials 2023: Pipeline Drugs, Companies, Therapies, Mechanism of Action, Route of
Benzinga | September 21, 2023